IL246879D0 - Apilimod compositions and methods for using same - Google Patents

Apilimod compositions and methods for using same

Info

Publication number
IL246879D0
IL246879D0 IL246879A IL24687916A IL246879D0 IL 246879 D0 IL246879 D0 IL 246879D0 IL 246879 A IL246879 A IL 246879A IL 24687916 A IL24687916 A IL 24687916A IL 246879 D0 IL246879 D0 IL 246879D0
Authority
IL
Israel
Prior art keywords
methods
same
apilimod
compositions
apilimod compositions
Prior art date
Application number
IL246879A
Other languages
Hebrew (he)
Original Assignee
Lam Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US201461931075P priority Critical
Priority to US201461931078P priority
Priority to US201462077127P priority
Priority to PCT/US2015/012733 priority patent/WO2015112888A1/en
Application filed by Lam Therapeutics Inc filed Critical Lam Therapeutics Inc
Publication of IL246879D0 publication Critical patent/IL246879D0/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53681989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL246879(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL246879A 2014-01-24 2016-07-21 Apilimod compositions and methods for using same IL246879D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US201461931075P true 2014-01-24 2014-01-24
US201461931078P true 2014-01-24 2014-01-24
US201462077127P true 2014-11-07 2014-11-07
PCT/US2015/012733 WO2015112888A1 (en) 2014-01-24 2015-01-23 Apilimod compositions and methods for using same

Publications (1)

Publication Number Publication Date
IL246879D0 true IL246879D0 (en) 2016-08-31

Family

ID=53681989

Family Applications (1)

Application Number Title Priority Date Filing Date
IL246879A IL246879D0 (en) 2014-01-24 2016-07-21 Apilimod compositions and methods for using same

Country Status (11)

Country Link
US (2) US10179135B2 (en)
EP (1) EP3096757A4 (en)
JP (1) JP2017503842A (en)
KR (1) KR20160126984A (en)
CN (1) CN106659716A (en)
AU (1) AU2015209133B2 (en)
CA (1) CA2937655A1 (en)
IL (1) IL246879D0 (en)
MX (1) MX2016009590A (en)
RU (2) RU2019107011A (en)
WO (1) WO2015112888A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3215158T3 (en) * 2014-11-07 2019-11-29 Ai Therapeutics Inc Apilimod for use in the treatment of renal cancer
EP3215159A1 (en) * 2014-11-07 2017-09-13 LAM Therapeutics, Inc. Apilimod for use in the treatment of colorectal cancer
WO2016118709A1 (en) * 2015-01-23 2016-07-28 Lam Therapeutics, Inc. Anti-viral compositions containing pikfyve inhibitors and use thereof
US20180078561A1 (en) * 2015-03-31 2018-03-22 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TW201717957A (en) * 2015-07-20 2017-06-01 藍治療公司 Methods for treating cancer using apilimod
BR112018009738A2 (en) * 2016-01-21 2018-12-04 Lam Therapeutics Inc biomarkers for apilimod cancer treatment
CN109952113A (en) * 2016-08-25 2019-06-28 人工智能治疗公司 Composition comprising PIKFYVE inhibitor and method relevant to the inhibition of RANK signal transduction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2555365A1 (en) 2004-02-06 2005-08-25 Elan Pharmaceuticals, Inc. Methods and compositions for treating tumors and metastatic disease
CA2563895C (en) * 2004-04-13 2012-10-16 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
CA2579096C (en) * 2004-09-08 2012-11-13 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds
WO2006124662A1 (en) 2005-05-13 2006-11-23 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
PL2385053T3 (en) 2005-11-17 2014-05-30 Osi Pharmaceuticals Llc Intermediates for the preparation of fused bicyclic mTOR inhibitors
ES2606313T3 (en) 2006-07-12 2017-03-23 University Of Tennessee Research Foundation Substituted acilanilides and methods of use thereof
JP5258331B2 (en) * 2008-03-03 2013-08-07 ロート製薬株式会社 Pharmaceutical composition containing a new quinolone antibacterial agent with improved photostability
US20110287018A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
US20170007613A1 (en) 2017-01-12
RU2016134406A (en) 2018-03-01
CN106659716A (en) 2017-05-10
US10179135B2 (en) 2019-01-15
MX2016009590A (en) 2017-05-09
WO2015112888A1 (en) 2015-07-30
AU2015209133A1 (en) 2016-08-11
RU2016134406A3 (en) 2018-09-20
AU2015209133B2 (en) 2019-10-03
CN106659716A8 (en) 2017-06-30
CA2937655A1 (en) 2015-07-30
US20190183902A1 (en) 2019-06-20
KR20160126984A (en) 2016-11-02
JP2017503842A (en) 2017-02-02
EP3096757A1 (en) 2016-11-30
EP3096757A4 (en) 2017-10-04
RU2019107011A (en) 2019-04-08

Similar Documents

Publication Publication Date Title
IL248143D0 (en) Methods and compositions for immunomodulation
EP3151846A4 (en) Methods and compositions for nuclease design
GB201406151D0 (en) Method
IL251420D0 (en) Triazolopyrazinones as pde1 inhibitors
RU2018124295A (en) Compositions and methods for immunouncology
GB201411197D0 (en) Composition and use thereof
IL246681D0 (en) Compounds and compositions for immunotherapy
IL246785D0 (en) Benzimidazol-2-amines as midh1 inhibitors
ZA201701244B (en) Carrier-antibody compositions and methods of making and using the same
IL250891D0 (en) Smyd inhibitors
HK1226398A1 (en) Benzimidazol-2-amines as midh1 inhibitors
HK1224376A1 (en) Methods and compositions for isolating exosomes
GB201418159D0 (en) Method
HK1232137A1 (en) Therapeutic compounds and compositions
IL248895D0 (en) Phosphatidylinositol -kinase inhibitors
GB201409558D0 (en) Method
RU2017116933A (en) Method and composition for stereolitography
GB201418469D0 (en) Method
IL252216D0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
GB201406155D0 (en) Method
SG11201610910QA (en) Methods and compositions using one-sided transposition
AU361515S (en) Dishrack
IL250998D0 (en) Microbial compositions and methods
IL246383D0 (en) Polyoxometalate and heteropolyoxometalate compositions and methods for their use
GB201417712D0 (en) Method